Cellcyte Genetics Corporation announced the appointment of Dr. Douglas Cerretti as Chief Science Officer and Director of Business Development, effective November 1, 2009. Dr. Cerretti is a biopharmaceutical research scientist with experience in drug development across different therapeutic areas. From 1984 to 2002 he served with Immunex and, after Immunex' acquisition in 2002, with Amgen in positions ranging from Staff Scientist through Scientific Director. Dr. Cerretti retired from Amgen in 2007. He is the author or co-author of more than 100 scientific publications and has over 40 issued US Patents to his name. Dr. Cerretti has been involved with CellCyte as an independent consultant, and, since November of 2008, has helped refine CellCyte's Interim Operating Plan. This plan defines how the Company will operate, with limited funding over the next six to twelve months, to continue the commercialization of its bioreactor product. Dr. Cerretti's appointment is the first of several planned appointments required to fully implement the Interim Operating Plan. CellCyte expects to formally adopt the plan by the end of 2009.

Cellcyte Genetics Corporation announced that effective September 10, 2009, Gary A. Reys resigned as the company's Chairman of the Board, CEO and as a member of the Board of Directors. On the same date, Ronald W. Berninger resigned as Secretary, Executive Vice President, Chief Scientific Officer and as a member of the Board of Directors. On September 8, 2009, the Securities and Exchange Commission filed a civil action against the company, alleging certain violations of the securities laws. On the same date, the Company entered into a Consent Decree with the Commission, in which the Company did not admit or deny any of the allegations contained in the civil action, but agreed not to violate the securities laws in the future. The Company was not required to pay any penalty in connection with the Consent Decree.

Cellcyte Genetics Corporation announced that in 2006 and 2007, the company paid a total of $25,000 and $90,000, respectively, on the execution of an intellectual property licensing agreement with U.S. Department of Veterans Affairs (VA). The Agreement relates to certain patents pending and contains royalty payment arrangements as well as funding guarantees. On or about February 5, 2009, the company received notice from the VA that it was terminating its agreement with the company. In response, on February 10, 2009, the company disputed the VAs asserted basis and right to terminate the Agreement on the grounds that the VA had committed a material breach of the Agreement by, among other things, providing incomplete data on which the patents were filed. Due to the uncertainty of the recoverability of the licenses and patents pending related to the VA intellectual property, the company recorded an impairment loss in its financial statements, effective July 1, 2008, for the full carrying amount.

CELLCYTE GENETICS CORP Files SEC form 8-K, Other Events

CellCyte Genetics Corp. Announces the Appointment of Douglas P. Cerretti, Ph.D. as Chief Science Officer and Director of Business Development

CELLCYTE GENETICS CORP Files SEC form 10-Q, Quarterly Report

CELLCYTE GENETICS CORP Files SEC form 10-Q, Quarterly Report

CELLCYTE GENETICS CORP Files SEC form 10-K, Annual Report

CELLCYTE GENETICS CORP Files SEC form 10-K, Annual Report

SEC Brings Fraud Charges Against Biotech Pump And Dump

CELLCYTE GENETICS CORP Files SEC form 10-Q, Quarterly Report

CellCyte Genetics Corp. Announces the Appointment of Douglas P. Cerretti, Ph.D. as Chief Science Officer and Director of Business Development